Survival of patients with colorectal carcinoma: Possible prognostic value of tissular carbohydrate antigen 19.9 determination

Cancer

Volumn 86, Issue 9, 1999, Pages 1675-1681

  Morales Gutiérrez, Carlos ^a   Vegh, Irene ^a,b   Colina, Francisco ^a   Gómez Cámara, Augustín ^a   García Carranza, Alberto ^a   Landa, J Ignacio ^a   Ballesteros, Dioniso ^a   Carreira, Patricia E ^a   Enriquez De Salamanca, Rafael ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

Carbohydrate antigen; Colorectal carcinoma; Cytosol tumor marker; Prognosis

Indexed keywords

CA 19-9 ANTIGEN; TUMOR MARKER;

ADULT; AGED; ANTIGEN DETECTION; ANTIGEN EXPRESSION; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; COLORECTAL CARCINOMA; EARLY DIAGNOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; PROGNOSIS;

EID: 0345062337     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19991101)86:9<1675::AID-CNCR8>3.3.CO;2-0     Document Type: Article

References (34)

1. Cohen AM, Misky BD, Schilsky RL. Cancers of gastrointestinal tract. In: De Vita VT Jr., Hellman S, Rosenberg SA, editors. Cancer principles and practice of oncology, chapter 32. Philadelphia: J.B. Lippincott-Raven Publishers, 1997; 971-1251.
2. National Institutes of Health. Annual cancer statistics review including cancer trends, 1950-1985 [NIH publication no. 88]. Bethesda, MD: National Institutes of Health, 1988:2789.
3. Glikman P, Vegh I, Pollina MA, Mosto A, Levy C. Ornithine decarboxylase activity (ODC), prolactin blood levels and estradiol and progesterone receptors in human breast cancer. Cancer 1987;60:2237-43.
4. Van Dalen A, Haering KJ, Barak V, Peretz T, Cremashi A, Geroni P, et al. Treatment response in metastatic breast cancer. A multicentre study comparing UICC criteria and tumor marker changes. Breast 1996;5:82-8.
5. Klang DT, Greenberg LJ, Kennedy BJ. Tumor marker kinetics in the monitoring of breast cancer. Cancer 1990;65:193-9.
6. Schwartz MR, Randolph RL, Panko WB. Carcinoembryonic antigen and steroid receptors in the cytosol of carcinoma of the breast. Cancer 1985;55:2464-71.
7. Koprowski H, Steplewiski Z, Mitchell K, Herlyn D, Fulner P. Colorectal carcinoma antigens detected by hybridoma antibodies. Somat Cell Genet 1979;5:957-72.
8. Koprowski H, Herlyn M, Steplewski Z, Sears HF. Specific antigen in serum in patients with colon carcinoma. Science 1981;212:53-5.
9. Bates SE. Clinical applications of serum tumor markers. Ann Intern Med 1991;115:632-8.
10. Heryln M, Sears HF, Steplewski Z, Koprowski H. Monoclonal antibody detection of circulating tumor-associated antigen. Presence of antigen in sera of patients with colorectal, gastric and pancreatic carcinoma. J Clin Immunol 1982;2:135-40.
11. Magnani JL, Nilson B, Brockhaus M, Zopf D, Steplewski Z, Koprowski H, et al. A monoclonal antibody-defined antigen associated with gastrointestinal cancer is a ganglioside containing sialylated lacto-N-fucopentaose II. J Biol Chem 1982; 257:14265-9.
12. Khoo SK, Warner NL, Lie JT, Mackay IR. Carcinoembryonic antigenic activity of tissue extracts: a quantitative study of malignant and benign neoplasm, cirrhotic liver, normal adult and fetal organs. Int J Cancer 1973;11:681-7.
13. Fucini C, Tommasini SM, Risi S, Malatantis G, Cardona G, Pacini G, et al. Follow-up colorectal cancer resected for cure. An experience with CEA, TPA, CA 19.9 analysis and second-look surgery. Dis Colon Rectum 1987;30:273-7.
14. Lorenzi M, Vindigni C, Minacci C, Tripodi SA, Iroatulam A, Petrioli R, et al. Histopathological and prognostic evaluation of immunohistochemical findings in colorectal cancer. Int J Biol Markers 1997;12:68-74.
15. International Union Against Cancer. In: Lobin LH, Wittekind C, editors. TNM classification of malignant tumors, 5th ed. New York: Wiley-Liss, Inc., 1997:66-9.
16. Jass JR, Sabin LH. Histological typing of intestinal tumors. World Health Organization. International histological classification of tumors. 2nd ed. Berlin: Springer-Velag 1987; 32-3.
17. Vegh I. Tissular tumor marker determination by autoanalyser technology. Madrid: Boletín Oficial de la Propiedad Industrial, 1997.
18. Lowry OH, Rosebrough NJ, Farr AL, Randal RJ. Protein measurement, with the Folin-phenol reagent. J Biol Chem 1951; 193:265-75.
19. Hemming AW, Davis NL, Kluftinger A, Robinson B, Quenville NF, Liserman B, et al. Prognostic markers of colorectal cancer: an evaluation of DNA content, epidermal growth factor receptor and KI-67. J Surg Oncol 1992;51:147-52.
20. Midiri G, Amanti C, Benedetti M, Campisi C, Santeusario G, Castagna G, et al. CEA tissue staining in colorectal cancer patients: a way to improve the usefulness of serial serum CEA elevation. Cancer 1985;55:2624-9.
21. Castelli M, Casale V, Segal FM. The biological and clinical significance of tumor markers in tissue extracts. Cancer Detec Prev 1983;6:61-6.
22. Quentmeier A, Möller P, Schwarz V, Abel U, Schalag P. Carcinoembryonic Antigen CA19.9 and CA 125 in normal and carcinomatous human colorectal tissue. Cancer 1987; 60:2261-6.
23. Imamura Y, Yasutake K, Yoshimura Y, Oya M, Matsushita K, Tokisue M, et al. Contents of tissue CEA and CA 19.9 in colonic polyp and colorectal cancer and their clinical significance. Gastroenterol Jpn 1990;25:186-92.
24. Okuda K, Kodara S, Watanabe M, et al. Utility of CA 19.9 and CEA as tumor markers for colorectal cancer. Comparison between serum levels and distribution. J Jpn Cancer 1986; 21:969-77.
25. Tabuchi Y, Deguchi H Saitoh Y. Carcinoembryonic antigen and carbohydrate antigen 19.9 levels of peripheral and draining venous blood in colorectal cancer patients. Correlation with histopathologic and immunohistochemical variables. Cancer 1988;62:1605-13.
26. Arends JW, Wiggers T, Schutte B, Thijs C, Verstijnen C, Hilgers J, et al. Monoclonal antibody (1116 NS 19.9) defined monosialoganglioside (GICA) in colorectal carcinoma in relation to stage, histopathology and DNA flow cytometry. Int J Cancer 1983;32:289-93.
27. Owens AH Jr. Tumor cell heterogeneity: a perspective. In: Owens AH Jr., Coffey S, Baylin SB, editors. Tumor cell heterogeneity: origins and implications. New York: Academic Press, 1982:3-6.
28. Cosimelli M, De Peppo F, Castelli M, Gianmarelli D, Schinara G, Castaldo P, et al. Multivariate analysis of a tissue CEA and CA 19.9 quantitative study in colorectal cancer patients. Dis Colon Rectum 1989;32:389-97.
29. Kiriyama K, Watanabe T, Sakamoto J, Akiyama S, Yamauchi M, Takagi H. Expression and clinical significance of type-1 blood group antigens (Lea, Leb, CA19.9) in colorectal cancer: comparison with CEA. Nippon Geka Gakkai Zasshi 1991; 92:320-30.
30. Narimatsu H, Iwasaki H, Nishihara S, Kimura H, Kudo T, Yamauchi Y, et al. Genetic evidence for Lewis enzyme, which synthesizes Type-I Lewis antigen in colon tissue, and intracellular localization of the enzyme. Cancer Res 1996;56: 330-8.
31. Benchimol S, Fuks A, Jothy S, Beauchemin N, Shirota K, Stanners CP. Carcinoembryonic antigen, a human tumor marker, functions as an intercellular adhesion molecule. Cell 1989;57:327-34.
32. Screaton RA, Penn LZ, Stanners CP. Carcinoembryonic antigen, a human tumor marker, cooperates with Myc and Bcl-2 in cellular transformation. J Cell Biol 1997;137:939-52.
33. Ono S. Studies on carcinoembryonic antigen (CEA), lactate dehydrogenase (LDH), and LDH isozymes in the tissue of colorectal carcinoma. Nippon Geka Gakkai Zasshi 1983;84: 336-48.
34. Kemeny N, Braun DW Jr. Prognostic factors in advanced colorectal carcinoma. Importance of Lactic Dehydrogenase level, performance status, and white blood cell count. Am J Med 1983;74:786-94.